The associations between anxiety/depression and plasma chromogranin A among healthy workers: Results from EHOP study

Chromogranin A (CgA) is regarded as an indicator of sympathetic tone and adrenomedullary system activity. Catestatin is one of CgA‐derived fragments through proteolytic processing. Many studies have confirmed the correlation between anxiety/depression and the salivary CgA level. The study was to investigate the associations between anxiety/depression and plasma CgA/catestatin levels in healthy workers without cardiovascular disease.

[1]  Wenjuan Gao,et al.  Gender differences in depression, anxiety, and stress among college students: A longitudinal study from China. , 2019, Journal of affective disorders.

[2]  B. Bordoni,et al.  Depression and anxiety in patients with chronic heart failure. , 2018, Future cardiology.

[3]  T. Kakamu,et al.  Salivary chromogranin A levels correlate with disease severity but do not reflect anxiety or personality of adult patients with atopic dermatitis , 2017, The Journal of dermatology.

[4]  C. Carlson,et al.  Glycosylated Chromogranin A in Heart Failure: Implications for Processing and Cardiomyocyte Calcium Homeostasis. , 2017, Circulation. Heart failure.

[5]  H. Brenner,et al.  Association of hypertension with depression and generalized anxiety symptoms in a large population-based sample of older adults , 2016, Journal of hypertension.

[6]  R. von Känel,et al.  The Monocyte-to-Lymphocyte Ratio Correlates with Psycho-Neuro-Inflammatory Factors in Patients with Stable Coronary Artery Disease , 2016, Neuroimmunomodulation.

[7]  M. Arnau,et al.  Mice lacking chromogranins exhibit increased aggressive and depression-like behaviour , 2015, Behavioural Brain Research.

[8]  Y. Gan,et al.  Depression and the risk of coronary heart disease: a meta-analysis of prospective cohort studies , 2014, BMC Psychiatry.

[9]  Jin-sheng Su,et al.  Usefulness of catestatin to predict malignant arrhythmia in patients with acute myocardial infarction , 2014, Peptides.

[10]  Lamberto Manzoli,et al.  Biological function and clinical relevance of chromogranin A and derived peptides , 2014, Endocrine connections.

[11]  Viola Vaccarino,et al.  Depression as a Risk Factor for Poor Prognosis Among Patients With Acute Coronary Syndrome: Systematic Review and Recommendations A Scientific Statement From the American Heart Association , 2014, Circulation.

[12]  L. Meng,et al.  Plasma levels and diagnostic value of catestatin in patients with heart failure , 2013, Peptides.

[13]  F. Delalande,et al.  Cateslytin, a Chromogranin A Derived Peptide Is Active against Staphylococcus aureus and Resistant to Degradation by Its Proteases , 2013, PloS one.

[14]  Ying Yang,et al.  Plasma catestatin level in patients with acute myocardial infarction and its correlation with ventricular remodelling , 2012, Postgraduate Medical Journal.

[15]  Tatsuya Hayashi,et al.  Increased salivary chromogranin A in women with severe negative mood states in the premenstrual phase , 2012, Journal of psychosomatic obstetrics and gynaecology.

[16]  Y. Loh,et al.  Chromogranin A and Derived Peptides in Health and Disease , 2012, Journal of Molecular Neuroscience.

[17]  W. Gao,et al.  Dramatic changes in catestatin are associated with hemodynamics in acute myocardial infarction , 2011, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

[18]  M. Toda,et al.  Levels of awakening salivary CgA in response to stress in healthy subjects , 2011, Environmental health and preventive medicine.

[19]  Chun-yan Zhou,et al.  The neuropeptide catestatin promotes vascular smooth muscle cell proliferation through the Ca2+-calcineurin-NFAT signaling pathway. , 2011, Biochemical and biophysical research communications.

[20]  J. Denollet,et al.  Anxiety and risk of incident coronary heart disease: a meta-analysis. , 2010, Journal of the American College of Cardiology.

[21]  S. Aydin,et al.  Alteration in chromogranin A, obestatin and total ghrelin levels of saliva and serum in epilepsy cases , 2010, Peptides.

[22]  T. Omland,et al.  Prognostic value of circulating chromogranin A levels in acute coronary syndromes , 2008, European heart journal.

[23]  J. Marksteiner,et al.  Monocyte migration: a novel effect and signaling pathways of catestatin. , 2008, European journal of pharmacology.

[24]  T. Angelone,et al.  The chromogranin A-derived vasostatins: new players in the endocrine heart. , 2008, Current medicinal chemistry.

[25]  M. Toda,et al.  Circadian rhythm of human salivary chromogranin A. , 2007, Biomedical research.

[26]  K. Tsukinoki,et al.  Expression and Localization of Chromogranin A Gene and Protein in Human Submandibular Gland , 2005, Cells Tissues Organs.

[27]  L. Lanfumey,et al.  Neurochemical and Behavioral Alterations in Glucocorticoid Receptor-Impaired Transgenic Mice after Chronic Mild Stress , 2004, The Journal of Neuroscience.

[28]  R. Snaith,et al.  The Hospital Anxiety And Depression Scale , 2003, Health and quality of life outcomes.

[29]  D. O'Connor,et al.  Early decline in the catecholamine release-inhibitory peptide catestatin in humans at genetic risk of hypertension. , 2002, Journal of hypertension.

[30]  T. T. Haug,et al.  The validity of the Hospital Anxiety and Depression Scale. An updated literature review. , 2002, Journal of psychosomatic research.

[31]  D. O'Connor,et al.  Novel autocrine feedback control of catecholamine release. A discrete chromogranin a fragment is a noncompetitive nicotinic cholinergic antagonist. , 1997, The Journal of clinical investigation.

[32]  P. Cryer,et al.  Plasma chromogranin A as a marker of sympathochromaffin activity in humans. , 1991, The American journal of physiology.

[33]  E. Gelpí,et al.  Time course of changes in serotonin and noradrenaline in rat brain after predictable or unpredictable shock , 1988, Brain Research.

[34]  C. Herrmann.  International experiences with the Hospital Anxiety and Depression Scale--a review of validation data and clinical results. , 1997, Journal of psychosomatic research.

[35]  D. O'Connor,et al.  Chromogranin A correlates with norepinephrine release rate. , 1992, Life sciences.

[36]  D. O'Connor,et al.  Human chromogranin A. Purification and characterization from catecholamine storage vesicles of human pheochromocytoma. , 1984, Hypertension.

[37]  S. Mahata,et al.  Online Supplement : Novel peptide isomer strategy for stable inhibition of catecholamine release : Application to hypertension , 2022 .